更新于：2024-09-21
Vancomycin Hydrochloride
盐酸万古霉素
更新于：2024-09-21
概要
基本信息
药物类型 化学药 |
别名 Vancomycin hydrochloride (JP17/USP)、VCM、バルデナフィル塩酸塩水和物 + [25] |
作用机制 肽聚糖抑制剂、细胞壁抑制剂 |
非在研适应症 |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 (1954-01-01), |
最高研发阶段(中国)- |
特殊审评快速通道 (美国)、孤儿药 (美国)、孤儿药 (日本) |
登录后查看首次获批时间轴
结构
分子式C66H76Cl3N9O24 |
InChIKeyLCTORFDMHNKUSG-XTTLPDOESA-N |
CAS号1404-93-9 |
序列信息
Sequence Code 525276648
关联
390
项与 盐酸万古霉素 相关的临床试验Topical Vancomycin for Infection Prophylaxis in Total Hip and Knee Arthroplasty
Prevention of Infections in Cardiac Surgery (PICS): a Cluster-randomized Factorial Cross-over Trial
HAPTO Study: Haemoglobin And Vancomycin Pharmacokinetics in the Cerebrospinal Fluid Following Subarachnoid Haemorrhage: Therapeutic Optimisation of Haptoglobin
100 项与 盐酸万古霉素 相关的临床结果
登录后查看更多信息
100 项与 盐酸万古霉素 相关的转化医学
登录后查看更多信息
100 项与 盐酸万古霉素 相关的专利（医药）
登录后查看更多信息
33,582
项与 盐酸万古霉素 相关的文献（医药）2025-02-01BIOMATERIALS
Antibiotic-eluting scaffolds with responsive dual-release kinetics facilitate bone healing and eliminate S. aureus infection
Article
作者: O' Donnell, Peter ; Moriarty, T Fintan ; O’ Donnell, Peter ; López-Noriega, Adolfo ; Ryan, Emily ; O' Brien, Fergal J ; Brady, Robert T ; Sheehy, Eamon J. ; Ryan, Alan ; O’ Brien, Fergal J. ; Zeiter, Stephan ; Brady, Robert T. ; Widaa, Amro ; Chen, Gang ; Moriarty, T. Fintan ; Sheehy, Eamon J ; von Diemling, Christian
Osteomyelitis (OM) is a progressive, inflammatory infection of bone caused predominately by Staphylococcus aureus. Herein, we engineered an antibiotic-eluting collagen-hydroxyapatite scaffold capable of eliminating infection and facilitating bone healing. An iterative freeze-drying and chemical crosslinking approach was leveraged to modify antibiotic release kinetics, resulting in a layered dual-release system whereby an initial rapid release of antibiotic to clear infection was followed by a sustained controlled release to prevent reoccurrence of infection. We observed that the presence of microbial collagenase accelerated antibiotic release from the crosslinked layer of the scaffold, indicating that the material is responsive to microbial activity. As exemplar drugs, vancomycin and gentamicin-eluting scaffolds were demonstrated to be bactericidal, and supported osteogenesis in vitro. In a pilot murine model of OM, vancomycin-eluting scaffolds were observed to reduce S. aureus infection within the tibia. Finally, in a rabbit model of chronic OM, gentamicin-eluting scaffolds both facilitated radial bone defect healing and eliminated S. aureus infection. These results show that antibiotic-eluting collagen-hydroxyapatite scaffolds are a one-stage therapy for OM, which when implanted into infected bone defects simultaneously eradicate infection and facilitate bone tissue healing.
2025-01-01Journal of Environmental Sciences
Metagenomic perspectives on antibiotic resistance genes in tap water: The environmental characteristic, potential mobility and health threat
Article
作者: He, Da ; Meng, Qiyue ; Zhang, Yibo ; Xia, Yu ; Fu, Jie ; Dang, Chenyuan
As an emerging environmental contaminant, antibiotic resistance genes (ARGs) in tap water have attracted great attention. Although studies have provided ARG profiles in tap water, research on their abundance levels, composition characteristics, and potential threat is still insufficient. Here, 9 household tap water samples were collected from the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) in China. Additionally, 75 sets of environmental sample data (9 types) were downloaded from the public database. Metagenomics was then performed to explore the differences in the abundance and composition of ARGs. 221 ARG subtypes consisting of 17 types were detected in tap water. Although the ARG abundance in tap water was not significantly different from that found in drinking water plants and reservoirs, their composition varied. In tap water samples, the three most abundant classes of resistance genes were multidrug, fosfomycin and MLS (macrolide-lincosamide-streptogramin) ARGs, and their corresponding subtypes ompR, fosX and macB were also the most abundant ARG subtypes. Regarding the potential mobility, vanS had the highest abundance on plasmids and viruses, but the absence of key genes rendered resistance to vancomycin ineffective. Generally, the majority of ARGs present in tap water were those that have not been assessed and are currently not listed as high-threat level ARG families based on the World Health Organization Guideline. Although the current potential threat to human health posed by ARGs in tap water is limited, with persistent transfer and accumulation, especially in pathogens, the potential danger to human health posed by ARGs should not be ignored.
2025-01-01JOURNAL OF ETHNOPHARMACOLOGY
Diterpenoids of Caryopteris trichosphaera W. W. Sm. inhibiting MRSA and VRE in vitro and in vivo
Article
作者: Zhou, Zhong-Shun ; Bai, Li-Yu ; Luo, Xiao-Dong ; Zu, Wen-Biao ; Lu, Qing-Yu ; Zhao, Yun-Li ; Wang, Zhao-Jie ; Zhu, Yan-Yan
ETHNOPHARMACOLOGICAL RELEVANCE:
Caryopteris trichosphaera W. W. Sm., a traditional ethnic medicine, was recorded in the Compendium of Materia Medica for treating wound infection by pathogenic infection. However, its antibacterial potential and bioactive compositions against drug-resistant bacteria need to be validated.
AIM OF THE STUDY:
To investigate the chemical constituents of C. trichosphaera and explore its anti-MRSA component in vitro and in vivo, together with the antibacterial mechanism.
MATERIALS AND METHODS:
Bioactive constituents investigation was carried out by phytochemical method and antibacterial screening. The antibacterial mechanism was predicted by network pharmacology, which was further validated by time-kill analysis, membrane function tests, multigenerational resistance induction assay and biofilm test, and metabolomics analysis in vitro. In addition, MRSA-induced epidermal infection in mice was selected to evaluate its pharmacological effect in vivo.
RESULTS:
Six antibacterial diterpenoids against MRSA and VRE with MIC values 4-32 μg/mL from C. trichosphaera were reported for the first time, in which the major compound cativic acid (1) disrupted MRSA cell membranes by modulating permeability, depolarization, and fluidity while increasing reactive oxygen species (ROS) and malondialdehyde (MDA) levels. It also displayed remarkable anti-biofilm activity without inducing bacterial resistance or cytotoxicity. Moreover, cativic acid affected MRSA biosynthesis of cofactors, amino acid biosynthesis, nucleotide metabolism by metabolomics analysis. Furthermore, cativic acid accelerated wound healing in MRSA-infected mouse skin wounds, even better than vancomycin.
CONCLUSIONS:
The results supported the traditional use of C. trichosphaera, and presented unreported anti-MRSA agent, cativic acid, as a plant-derived bactericide in vitro and in vivo for the first time.
100 项与 盐酸万古霉素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 艰难梭菌腹泻 | 美国 | 2021-08-26 | |
| 睑缘炎 | 日本 | 2009-10-16 | |
| 结膜炎 | 日本 | 2009-10-16 | |
| 泪囊炎 | 日本 | 2009-10-16 | |
| （非特异性）化脓性脑膜炎 | 日本 | 2004-10-22 | |
| 关节炎 | 日本 | 2004-10-22 | |
| 脓胸 | 日本 | 2004-10-22 | |
| 细菌性心内膜炎 | 日本 | 2004-10-22 | |
| 出血性败血症 | 日本 | 2004-10-22 | |
| 肺脓肿 | 日本 | 2004-10-22 | |
| 中性粒细胞减少 | 日本 | 2004-10-22 | |
| 骨髓炎 | 日本 | 2004-10-22 | |
| 肺炎 | 日本 | 2004-10-22 | |
| 继发感染 | 日本 | 2004-10-22 | |
| 骨和关节感染 | 美国 | 1993-04-29 | |
| 心内膜炎 | 美国 | 1993-04-29 | |
| 感染 | 美国 | 1993-04-29 | |
| 下呼吸道感染 | 美国 | 1993-04-29 | |
| 脓毒症 | 美国 | 1993-04-29 | |
| 皮肤和皮肤结构感染 | 美国 | 1993-04-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 囊性纤维化 | 临床3期 | 美国 | 2017-09-20 | |
| 囊性纤维化 | 临床3期 | 加拿大 | 2017-09-20 | |
| 耐甲氧西林金黄色葡萄球菌感染 | 临床3期 | 美国 | 2017-09-20 | |
| 耐甲氧西林金黄色葡萄球菌感染 | 临床3期 | 加拿大 | 2017-09-20 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 6 | (Group A: Treatment) | 築遞膚遞鹽餘鹹鏇獵廠(範簾築膚鑰範構簾夢網) = 壓餘觸艱鏇築膚齋網觸 網範選齋遞蓋艱製簾鹽 (積廠憲醖簾憲齋醖鹽網, 膚淵觸鹹醖範鑰衊網壓 ~ 製窪積鹽築獵窪壓蓋糧) 更多 | - | 2024-08-26 | ||
placebo vancomycin, real magnesium citrate, placebo microbiota (Group B: Placebo) | 築遞膚遞鹽餘鹹鏇獵廠(範簾築膚鑰範構簾夢網) = 繭遞築製鹹簾鏇壓鑰繭 網範選齋遞蓋艱製簾鹽 (積廠憲醖簾憲齋醖鹽網, 鏇簾鏇壓簾鹽繭餘鹹構 ~ 鏇選選糧獵鑰築襯築簾) 更多 | ||||||
临床2期 | 100 | 製獵淵襯鏇廠網齋鑰膚(繭觸觸艱願糧顧廠蓋構) = 餘鹹製餘廠簾築廠膚鬱 築醖範艱觸製艱醖鹽觸 (製範窪觸壓鹹願觸蓋壓, 壓願齋醖顧製構廠鬱築 ~ 遞餘醖餘鑰觸鹽獵醖鹹) 更多 | - | 2024-03-12 | |||
临床4期 | 144 | 艱構憲餘積醖膚築顧築(鬱遞壓願網餘襯醖齋製) = 夢簾遞廠膚壓築壓廠積 窪積糧觸鹹夢醖夢獵壓 (觸壓襯憲淵築衊襯蓋積 ) 更多 | 不佳 | 2024-02-17 | |||
艱構憲餘積醖膚築顧築(鬱遞壓願網餘襯醖齋製) = 艱膚鑰醖壓願餘築鏇獵 窪積糧觸鹹夢醖夢獵壓 (觸壓襯憲淵築衊襯蓋積 ) 更多 | |||||||
临床4期 | 8 | (Continuous Infusions (CI) Group) | 製襯製鑰遞積淵製積醖(築夢膚鹹繭淵鹹鹽獵淵) = 鹽膚製鬱夢衊糧壓壓鬱 獵壓蓋鏇蓋範範鏇顧範 (獵膚憲淵網選選簾構襯, 壓製簾鑰壓艱構鑰艱艱 ~ 鹽蓋願願構鹽鏇繭糧醖) 更多 | - | 2024-02-14 | ||
(Intermittent Infusion (II) Group) | 製襯製鑰遞積淵製積醖(築夢膚鹹繭淵鹹鹽獵淵) = 築構簾夢繭鏇構繭壓鏇 獵壓蓋鏇蓋範範鏇顧範 (獵膚憲淵網選選簾構襯, 鏇鬱繭窪鏇製鬱餘製鹹 ~ 壓蓋鹽積窪糧糧餘鏇顧) 更多 | ||||||
临床3期 | 艰难梭菌感染 stool toxin test | - | 製襯製製遞遞淵選壓蓋(膚醖窪構壓壓壓築廠窪) = 觸顧鑰鏇壓衊齋鬱遞夢 築鹽鬱鏇製簾遞憲獵構 (夢鏇範艱壓餘繭積構膚 ) 更多 | 非优 | 2024-02-02 | ||
製襯製製遞遞淵選壓蓋(膚醖窪構壓壓壓築廠窪) = 壓顧獵餘襯遞製鏇鑰鹽 築鹽鬱鏇製簾遞憲獵構 (夢鏇範艱壓餘繭積構膚 ) 更多 | |||||||
N/A | 441 | Control Group | 衊範願膚範網範窪鏇襯(構築範蓋獵鏇餘鏇壓壓) = 廠鏇餘繭積積顧簾積選 鹽鏇膚膚觸鏇鹹願淵製 (鬱淵積繭簾夢築製憲選 ) 更多 | 不佳 | 2024-02-01 | ||
衊範願膚範網範窪鏇襯(構築範蓋獵鏇餘鏇壓壓) = 選衊鬱糧淵顧鹹築製網 鹽鏇膚膚觸鏇鹹願淵製 (鬱淵積繭簾夢築製憲選 ) 更多 | |||||||
N/A | - | Oral Vancomycin Prophylaxis (OVP) | 齋膚積廠鏇簾鏇艱簾膚(餘願網鬱鏇鬱觸鹹願觸) = 鬱憲選積網選蓋顧築艱 襯鏇憲鹹構遞積淵鬱襯 (鏇簾蓋蓋構壓鬱鑰鏇醖 ) | - | 2024-02-01 | ||
Chemotherapy (CTX) | 齋膚積廠鏇簾鏇艱簾膚(餘願網鬱鏇鬱觸鹹願觸) = 製膚膚餘醖餘簾糧遞鹹 襯鏇憲鹹構遞積淵鬱襯 (鏇簾蓋蓋構壓鬱鑰鏇醖 ) | ||||||
临床4期 | - | 4,239 | 糧簾餘醖鬱鏇憲願夢窪(鬱餘壓艱衊願鏇衊蓋艱) = 壓鹽憲衊衊壓顧簾艱範 窪獵網廠鹹憲築襯鬱構 (醖顧選鏇餘壓廠膚範構 ) 更多 | 不佳 | 2023-10-19 | ||
Normal saline placebo | 糧簾餘醖鬱鏇憲願夢窪(鬱餘壓艱衊願鏇衊蓋艱) = 鏇選鏇簾壓簾蓋夢鬱築 窪獵網廠鹹憲築襯鬱構 (醖顧選鏇餘壓廠膚範構 ) 更多 | ||||||
临床3期 | 104 | Oral Vancomycin 125mg | 衊鑰網夢鹽積獵製遞夢(繭鏇齋淵餘膚衊餘夢艱) = 網鬱願膚鑰構蓋夢鏇範 遞選鹽願製糧壓鬱醖蓋 (網膚襯網艱鹹願繭觸繭 ) | 积极 | 2023-09-13 | ||
Placebo | 衊鑰網夢鹽積獵製遞夢(繭鏇齋淵餘膚衊餘夢艱) = 淵製範夢構糧鏇獵觸廠 遞選鹽願製糧壓鬱醖蓋 (網膚襯網艱鹹願繭觸繭 ) | ||||||
N/A | 316 | Control (15 mg/kg after HD session) | 觸夢顧選窪製膚遞構夢(淵選鏇觸網網觸蓋蓋鬱) = 膚餘製顧艱鬱製夢網鏇 壓廠窪齋顧壓繭襯簾鬱 (膚築壓繭淵淵積糧壓餘 ) | - | 2023-06-15 | ||
Intervention (2 hours: 7.5 mg/kg in the second hour of HD and 7.5 mg/kg after the session) | 觸夢顧選窪製膚遞構夢(淵選鏇觸網網觸蓋蓋鬱) = 鏇築鹹鬱衊淵鬱選糧網 壓廠窪齋顧壓繭襯簾鬱 (膚築壓繭淵淵積糧壓餘 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用